Using AI to Reduce Bleeding and Clotting Risks in Myeloid Malignancy Patients
Mitigating Hematologic Adverse Events in Patients with Myeloid Malignancies: A Novel Causal Artificial Intelligence Approach
This project uses advanced artificial intelligence to better predict and prevent serious bleeding and clotting issues in people with myeloid malignancies.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Harvard Medical School NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project ID | NIH-11117039 on NIH RePORTER |
What this research studies
Patients with myeloid malignancies often face life-threatening complications like blood clots and bleeding. Current methods for predicting these risks aren't always precise enough for each individual. This project aims to create a new artificial intelligence system that can look at a patient's unique health information, including their genetics and lab results, to give a much more accurate and personalized risk assessment. By understanding the underlying causes of these complications, the AI can help doctors make better treatment decisions to reduce these risks.
Who could benefit from this research
Good fit: This research is relevant for patients diagnosed with myeloid malignancies who are at risk for or have experienced blood clots or bleeding complications.
Not a fit: Patients without myeloid malignancies or those not experiencing or at risk for hematologic complications would not directly benefit from this specific research.
Why it matters
Potential benefit: If successful, this work could lead to personalized treatment plans that significantly lower the chances of dangerous bleeding and clotting for patients with myeloid malignancies.
How similar studies have performed: While previous studies have identified some risk factors, this approach is novel in its use of causal artificial intelligence to provide personalized risk prediction and treatment suggestions.
Where this research is happening
Boston, United States
- Harvard Medical School — Boston, United States (Active)
Researchers
- Principal investigator: Yu, Kun-Hsing — Harvard Medical School
- Study coordinator: Yu, Kun-Hsing
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.